〔Abstract〕 Objective To explore the clinical value of deoxyribonucleic acid(DNA) quantitative analysis in cervical cancer screening. Methods A total of 4825 women who underwent cervical cancer screening in Shenzhen Longgang People's Hospital from January 2017 to February 2018 were selected and screened by DNA quantitative analysis. The DNA ploidy of the nucleus was calculated. If no aneuploid cells were found, routine screening was recommended. If the number of aneuploid cells is 1 or 2, reexamination was recommended once every 6 months. Colposcopic biopsy was recommended when the number was ≥ 3. Results Among 4825 women, 3867 (80.1 %) were recommended for regular screening; 864 patients (17.9%) were recommended to be re-examined in 6 months. Colposcopic biopsy was performed in 94 cases (1.9 %). Biopsy results showed precancerous lesions in 66 cases (1.7 %), including 30 cases of cervical intraepithelial neoplasia (CIN) I, 24 cases of CIN Ⅱ and 12 cases of CIN Ⅲ. There were 21 cases of cervical cancer (0.5 %), including 16 cases of early cancer and 5 cases of invasive cancer. Conclusion It is important for the prevention and treatment of cervical cancer to use DNA quantitative detection technology to screen cervical cancer and make follow-up plan or biopsy under colposcope according to the results.